nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—ABCB1—Estramustine—prostate cancer	0.0907	0.2	CbGbCtD
Scopolamine—ABCB1—Cabazitaxel—prostate cancer	0.0598	0.132	CbGbCtD
Scopolamine—ABCB1—Estrone—prostate cancer	0.0585	0.129	CbGbCtD
Scopolamine—ABCB1—Ethinyl Estradiol—prostate cancer	0.0521	0.115	CbGbCtD
Scopolamine—ABCB1—Conjugated Estrogens—prostate cancer	0.0382	0.0843	CbGbCtD
Scopolamine—ABCB1—Mitoxantrone—prostate cancer	0.0348	0.0767	CbGbCtD
Scopolamine—ABCB1—Estradiol—prostate cancer	0.0336	0.074	CbGbCtD
Scopolamine—ABCB1—Prednisone—prostate cancer	0.0289	0.0637	CbGbCtD
Scopolamine—CHRM3—ureter—prostate cancer	0.0273	0.347	CbGeAlD
Scopolamine—ABCB1—Etoposide—prostate cancer	0.0219	0.0483	CbGbCtD
Scopolamine—ABCB1—Docetaxel—prostate cancer	0.0201	0.0442	CbGbCtD
Scopolamine—ABCB1—Doxorubicin—prostate cancer	0.015	0.033	CbGbCtD
Scopolamine—SI—prostate gland—prostate cancer	0.0147	0.187	CbGeAlD
Scopolamine—SI—testis—prostate cancer	0.00649	0.0825	CbGeAlD
Scopolamine—CHRM5—epithelium—prostate cancer	0.00418	0.0531	CbGeAlD
Scopolamine—CHRM2—prostate gland—prostate cancer	0.0039	0.0496	CbGeAlD
Scopolamine—CHRM1—prostate gland—prostate cancer	0.00355	0.0452	CbGeAlD
Scopolamine—CHRM4—testis—prostate cancer	0.00321	0.0408	CbGeAlD
Scopolamine—CHRM3—prostate gland—prostate cancer	0.00318	0.0404	CbGeAlD
Scopolamine—CHRM3—renal system—prostate cancer	0.00217	0.0276	CbGeAlD
Scopolamine—CHRM3—urethra—prostate cancer	0.00213	0.0271	CbGeAlD
Scopolamine—CHRM3—testis—prostate cancer	0.0014	0.0178	CbGeAlD
Scopolamine—ABCB1—prostate gland—prostate cancer	0.00124	0.0157	CbGeAlD
Scopolamine—ABCB1—seminal vesicle—prostate cancer	0.00105	0.0133	CbGeAlD
Scopolamine—ABCB1—epithelium—prostate cancer	0.000909	0.0116	CbGeAlD
Scopolamine—ABCB1—renal system—prostate cancer	0.000843	0.0107	CbGeAlD
Scopolamine—ABCB1—urethra—prostate cancer	0.000828	0.0105	CbGeAlD
Scopolamine—ABCB1—bone marrow—prostate cancer	0.000637	0.00811	CbGeAlD
Scopolamine—ABCB1—testis—prostate cancer	0.000545	0.00693	CbGeAlD
Scopolamine—ABCB1—lymph node—prostate cancer	0.000395	0.00502	CbGeAlD
Scopolamine—Asthenia—Conjugated Estrogens—prostate cancer	0.00032	0.00103	CcSEcCtD
Scopolamine—Urinary tract disorder—Docetaxel—prostate cancer	0.000319	0.00103	CcSEcCtD
Scopolamine—Bradycardia—Capecitabine—prostate cancer	0.000319	0.00103	CcSEcCtD
Scopolamine—Pruritus—Goserelin—prostate cancer	0.000318	0.00103	CcSEcCtD
Scopolamine—Somnolence—Estradiol—prostate cancer	0.000317	0.00102	CcSEcCtD
Scopolamine—Urethral disorder—Docetaxel—prostate cancer	0.000317	0.00102	CcSEcCtD
Scopolamine—Pruritus—Conjugated Estrogens—prostate cancer	0.000315	0.00102	CcSEcCtD
Scopolamine—Visual impairment—Docetaxel—prostate cancer	0.000311	0.001	CcSEcCtD
Scopolamine—Pharyngitis—Capecitabine—prostate cancer	0.000311	0.001	CcSEcCtD
Scopolamine—Hypotension—Mitoxantrone—prostate cancer	0.00031	0.001	CcSEcCtD
Scopolamine—Urinary tract disorder—Capecitabine—prostate cancer	0.000309	0.000996	CcSEcCtD
Scopolamine—Fatigue—Estradiol—prostate cancer	0.000307	0.00099	CcSEcCtD
Scopolamine—Urethral disorder—Capecitabine—prostate cancer	0.000307	0.000988	CcSEcCtD
Scopolamine—Pain—Estradiol—prostate cancer	0.000305	0.000982	CcSEcCtD
Scopolamine—Constipation—Estradiol—prostate cancer	0.000305	0.000982	CcSEcCtD
Scopolamine—Vertigo—Etoposide—prostate cancer	0.000304	0.00098	CcSEcCtD
Scopolamine—Eye disorder—Docetaxel—prostate cancer	0.000302	0.000973	CcSEcCtD
Scopolamine—Visual impairment—Capecitabine—prostate cancer	0.000302	0.000972	CcSEcCtD
Scopolamine—Flushing—Docetaxel—prostate cancer	0.0003	0.000967	CcSEcCtD
Scopolamine—Dizziness—Goserelin—prostate cancer	0.000297	0.000958	CcSEcCtD
Scopolamine—Somnolence—Mitoxantrone—prostate cancer	0.000295	0.000952	CcSEcCtD
Scopolamine—Dizziness—Conjugated Estrogens—prostate cancer	0.000295	0.000949	CcSEcCtD
Scopolamine—Feeling abnormal—Estradiol—prostate cancer	0.000294	0.000947	CcSEcCtD
Scopolamine—Eye disorder—Capecitabine—prostate cancer	0.000292	0.000942	CcSEcCtD
Scopolamine—Flushing—Capecitabine—prostate cancer	0.00029	0.000936	CcSEcCtD
Scopolamine—Dry skin—Epirubicin—prostate cancer	0.000289	0.000931	CcSEcCtD
Scopolamine—Arrhythmia—Docetaxel—prostate cancer	0.000289	0.00093	CcSEcCtD
Scopolamine—Fatigue—Mitoxantrone—prostate cancer	0.000286	0.000923	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000286	0.000922	CcSEcCtD
Scopolamine—Vomiting—Goserelin—prostate cancer	0.000286	0.000921	CcSEcCtD
Scopolamine—Constipation—Mitoxantrone—prostate cancer	0.000284	0.000915	CcSEcCtD
Scopolamine—Pain—Mitoxantrone—prostate cancer	0.000284	0.000915	CcSEcCtD
Scopolamine—Bradycardia—Prednisone—prostate cancer	0.000284	0.000914	CcSEcCtD
Scopolamine—Rash—Goserelin—prostate cancer	0.000284	0.000914	CcSEcCtD
Scopolamine—Dermatitis—Goserelin—prostate cancer	0.000283	0.000913	CcSEcCtD
Scopolamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000283	0.000913	CcSEcCtD
Scopolamine—Mental disorder—Docetaxel—prostate cancer	0.000283	0.000912	CcSEcCtD
Scopolamine—Body temperature increased—Estradiol—prostate cancer	0.000282	0.000908	CcSEcCtD
Scopolamine—Abdominal pain—Estradiol—prostate cancer	0.000282	0.000908	CcSEcCtD
Scopolamine—Headache—Goserelin—prostate cancer	0.000282	0.000908	CcSEcCtD
Scopolamine—Erythema—Docetaxel—prostate cancer	0.000281	0.000907	CcSEcCtD
Scopolamine—Rash—Conjugated Estrogens—prostate cancer	0.000281	0.000905	CcSEcCtD
Scopolamine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000281	0.000904	CcSEcCtD
Scopolamine—Arrhythmia—Capecitabine—prostate cancer	0.00028	0.000901	CcSEcCtD
Scopolamine—Headache—Conjugated Estrogens—prostate cancer	0.000279	0.000899	CcSEcCtD
Scopolamine—Confusional state—Etoposide—prostate cancer	0.000279	0.000898	CcSEcCtD
Scopolamine—Muscular weakness—Epirubicin—prostate cancer	0.000278	0.000896	CcSEcCtD
Scopolamine—Hallucination—Prednisone—prostate cancer	0.000277	0.000894	CcSEcCtD
Scopolamine—Mental disorder—Capecitabine—prostate cancer	0.000274	0.000883	CcSEcCtD
Scopolamine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000274	0.000882	CcSEcCtD
Scopolamine—Erythema—Capecitabine—prostate cancer	0.000272	0.000878	CcSEcCtD
Scopolamine—Dysphagia—Epirubicin—prostate cancer	0.000272	0.000878	CcSEcCtD
Scopolamine—Tachycardia—Etoposide—prostate cancer	0.00027	0.000869	CcSEcCtD
Scopolamine—Skin disorder—Etoposide—prostate cancer	0.000268	0.000865	CcSEcCtD
Scopolamine—Dry skin—Doxorubicin—prostate cancer	0.000267	0.000861	CcSEcCtD
Scopolamine—Nausea—Goserelin—prostate cancer	0.000267	0.000861	CcSEcCtD
Scopolamine—Hyperhidrosis—Etoposide—prostate cancer	0.000267	0.000861	CcSEcCtD
Scopolamine—Nausea—Conjugated Estrogens—prostate cancer	0.000265	0.000853	CcSEcCtD
Scopolamine—Abdominal pain—Mitoxantrone—prostate cancer	0.000263	0.000846	CcSEcCtD
Scopolamine—Body temperature increased—Mitoxantrone—prostate cancer	0.000263	0.000846	CcSEcCtD
Scopolamine—Eye disorder—Prednisone—prostate cancer	0.000261	0.000839	CcSEcCtD
Scopolamine—Flushing—Prednisone—prostate cancer	0.000259	0.000834	CcSEcCtD
Scopolamine—Hypotension—Etoposide—prostate cancer	0.000258	0.000832	CcSEcCtD
Scopolamine—Muscular weakness—Doxorubicin—prostate cancer	0.000257	0.000829	CcSEcCtD
Scopolamine—Vision blurred—Capecitabine—prostate cancer	0.000257	0.000827	CcSEcCtD
Scopolamine—Asthenia—Estradiol—prostate cancer	0.000256	0.000824	CcSEcCtD
Scopolamine—Tremor—Capecitabine—prostate cancer	0.000255	0.000822	CcSEcCtD
Scopolamine—Dysuria—Epirubicin—prostate cancer	0.000255	0.000821	CcSEcCtD
Scopolamine—Pruritus—Estradiol—prostate cancer	0.000252	0.000813	CcSEcCtD
Scopolamine—Dysphagia—Doxorubicin—prostate cancer	0.000252	0.000812	CcSEcCtD
Scopolamine—Arrhythmia—Prednisone—prostate cancer	0.000249	0.000802	CcSEcCtD
Scopolamine—Somnolence—Etoposide—prostate cancer	0.000246	0.000792	CcSEcCtD
Scopolamine—Vertigo—Capecitabine—prostate cancer	0.000245	0.000789	CcSEcCtD
Scopolamine—Mental disorder—Prednisone—prostate cancer	0.000244	0.000787	CcSEcCtD
Scopolamine—Drowsiness—Epirubicin—prostate cancer	0.000243	0.000783	CcSEcCtD
Scopolamine—Erythema—Prednisone—prostate cancer	0.000243	0.000782	CcSEcCtD
Scopolamine—Asthenia—Mitoxantrone—prostate cancer	0.000238	0.000768	CcSEcCtD
Scopolamine—Fatigue—Etoposide—prostate cancer	0.000238	0.000768	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000238	0.000767	CcSEcCtD
Scopolamine—Pain—Etoposide—prostate cancer	0.000236	0.000761	CcSEcCtD
Scopolamine—Constipation—Etoposide—prostate cancer	0.000236	0.000761	CcSEcCtD
Scopolamine—Conjunctivitis—Epirubicin—prostate cancer	0.000236	0.000761	CcSEcCtD
Scopolamine—Dizziness—Estradiol—prostate cancer	0.000236	0.00076	CcSEcCtD
Scopolamine—Dysuria—Doxorubicin—prostate cancer	0.000236	0.000759	CcSEcCtD
Scopolamine—Dry mouth—Docetaxel—prostate cancer	0.000234	0.000755	CcSEcCtD
Scopolamine—Sweating—Epirubicin—prostate cancer	0.000233	0.00075	CcSEcCtD
Scopolamine—Confusional state—Docetaxel—prostate cancer	0.000232	0.000746	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.00023	0.000742	CcSEcCtD
Scopolamine—Oedema—Docetaxel—prostate cancer	0.00023	0.00074	CcSEcCtD
Scopolamine—Vision blurred—Prednisone—prostate cancer	0.000229	0.000737	CcSEcCtD
Scopolamine—Feeling abnormal—Etoposide—prostate cancer	0.000228	0.000734	CcSEcCtD
Scopolamine—Dry mouth—Capecitabine—prostate cancer	0.000227	0.000731	CcSEcCtD
Scopolamine—Vomiting—Estradiol—prostate cancer	0.000227	0.00073	CcSEcCtD
Scopolamine—Nervous system disorder—Docetaxel—prostate cancer	0.000225	0.000726	CcSEcCtD
Scopolamine—Rash—Estradiol—prostate cancer	0.000225	0.000724	CcSEcCtD
Scopolamine—Drowsiness—Doxorubicin—prostate cancer	0.000225	0.000724	CcSEcCtD
Scopolamine—Dermatitis—Estradiol—prostate cancer	0.000225	0.000724	CcSEcCtD
Scopolamine—Confusional state—Capecitabine—prostate cancer	0.000224	0.000722	CcSEcCtD
Scopolamine—Tachycardia—Docetaxel—prostate cancer	0.000224	0.000722	CcSEcCtD
Scopolamine—Headache—Estradiol—prostate cancer	0.000223	0.00072	CcSEcCtD
Scopolamine—Skin disorder—Docetaxel—prostate cancer	0.000223	0.000719	CcSEcCtD
Scopolamine—Agitation—Prednisone—prostate cancer	0.000223	0.000719	CcSEcCtD
Scopolamine—Oedema—Capecitabine—prostate cancer	0.000222	0.000716	CcSEcCtD
Scopolamine—Bradycardia—Epirubicin—prostate cancer	0.000222	0.000715	CcSEcCtD
Scopolamine—Abdominal pain—Etoposide—prostate cancer	0.000218	0.000704	CcSEcCtD
Scopolamine—Body temperature increased—Etoposide—prostate cancer	0.000218	0.000704	CcSEcCtD
Scopolamine—Conjunctivitis—Doxorubicin—prostate cancer	0.000218	0.000704	CcSEcCtD
Scopolamine—Nervous system disorder—Capecitabine—prostate cancer	0.000218	0.000703	CcSEcCtD
Scopolamine—Vertigo—Prednisone—prostate cancer	0.000218	0.000702	CcSEcCtD
Scopolamine—Tachycardia—Capecitabine—prostate cancer	0.000217	0.000699	CcSEcCtD
Scopolamine—Pharyngitis—Epirubicin—prostate cancer	0.000216	0.000697	CcSEcCtD
Scopolamine—Skin disorder—Capecitabine—prostate cancer	0.000216	0.000696	CcSEcCtD
Scopolamine—Sweating—Doxorubicin—prostate cancer	0.000215	0.000694	CcSEcCtD
Scopolamine—Urinary tract disorder—Epirubicin—prostate cancer	0.000215	0.000694	CcSEcCtD
Scopolamine—Hyperhidrosis—Capecitabine—prostate cancer	0.000215	0.000693	CcSEcCtD
Scopolamine—Hypotension—Docetaxel—prostate cancer	0.000215	0.000691	CcSEcCtD
Scopolamine—Urethral disorder—Epirubicin—prostate cancer	0.000214	0.000689	CcSEcCtD
Scopolamine—Nausea—Estradiol—prostate cancer	0.000212	0.000682	CcSEcCtD
Scopolamine—Vomiting—Mitoxantrone—prostate cancer	0.000211	0.000681	CcSEcCtD
Scopolamine—Visual impairment—Epirubicin—prostate cancer	0.00021	0.000677	CcSEcCtD
Scopolamine—Rash—Mitoxantrone—prostate cancer	0.000209	0.000675	CcSEcCtD
Scopolamine—Dermatitis—Mitoxantrone—prostate cancer	0.000209	0.000674	CcSEcCtD
Scopolamine—Headache—Mitoxantrone—prostate cancer	0.000208	0.000671	CcSEcCtD
Scopolamine—Hypotension—Capecitabine—prostate cancer	0.000208	0.000669	CcSEcCtD
Scopolamine—Bradycardia—Doxorubicin—prostate cancer	0.000205	0.000662	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000205	0.000661	CcSEcCtD
Scopolamine—Somnolence—Docetaxel—prostate cancer	0.000204	0.000658	CcSEcCtD
Scopolamine—Eye disorder—Epirubicin—prostate cancer	0.000204	0.000656	CcSEcCtD
Scopolamine—Flushing—Epirubicin—prostate cancer	0.000202	0.000652	CcSEcCtD
Scopolamine—Pharyngitis—Doxorubicin—prostate cancer	0.0002	0.000645	CcSEcCtD
Scopolamine—Urinary tract disorder—Doxorubicin—prostate cancer	0.000199	0.000642	CcSEcCtD
Scopolamine—Asthenia—Etoposide—prostate cancer	0.000198	0.000639	CcSEcCtD
Scopolamine—Oedema—Prednisone—prostate cancer	0.000198	0.000638	CcSEcCtD
Scopolamine—Fatigue—Docetaxel—prostate cancer	0.000198	0.000638	CcSEcCtD
Scopolamine—Urethral disorder—Doxorubicin—prostate cancer	0.000198	0.000637	CcSEcCtD
Scopolamine—Nausea—Mitoxantrone—prostate cancer	0.000197	0.000636	CcSEcCtD
Scopolamine—Pain—Docetaxel—prostate cancer	0.000196	0.000633	CcSEcCtD
Scopolamine—Constipation—Docetaxel—prostate cancer	0.000196	0.000633	CcSEcCtD
Scopolamine—Pruritus—Etoposide—prostate cancer	0.000195	0.00063	CcSEcCtD
Scopolamine—Arrhythmia—Epirubicin—prostate cancer	0.000195	0.000628	CcSEcCtD
Scopolamine—Visual impairment—Doxorubicin—prostate cancer	0.000194	0.000626	CcSEcCtD
Scopolamine—Nervous system disorder—Prednisone—prostate cancer	0.000194	0.000626	CcSEcCtD
Scopolamine—Tachycardia—Prednisone—prostate cancer	0.000193	0.000623	CcSEcCtD
Scopolamine—Skin disorder—Prednisone—prostate cancer	0.000192	0.00062	CcSEcCtD
Scopolamine—Fatigue—Capecitabine—prostate cancer	0.000192	0.000618	CcSEcCtD
Scopolamine—Hyperhidrosis—Prednisone—prostate cancer	0.000191	0.000617	CcSEcCtD
Scopolamine—Mental disorder—Epirubicin—prostate cancer	0.000191	0.000615	CcSEcCtD
Scopolamine—Pain—Capecitabine—prostate cancer	0.00019	0.000613	CcSEcCtD
Scopolamine—Constipation—Capecitabine—prostate cancer	0.00019	0.000613	CcSEcCtD
Scopolamine—Erythema—Epirubicin—prostate cancer	0.00019	0.000612	CcSEcCtD
Scopolamine—Feeling abnormal—Docetaxel—prostate cancer	0.000189	0.00061	CcSEcCtD
Scopolamine—Eye disorder—Doxorubicin—prostate cancer	0.000189	0.000607	CcSEcCtD
Scopolamine—Flushing—Doxorubicin—prostate cancer	0.000187	0.000603	CcSEcCtD
Scopolamine—Feeling abnormal—Capecitabine—prostate cancer	0.000183	0.00059	CcSEcCtD
Scopolamine—Dizziness—Etoposide—prostate cancer	0.000183	0.000589	CcSEcCtD
Scopolamine—Abdominal pain—Docetaxel—prostate cancer	0.000182	0.000585	CcSEcCtD
Scopolamine—Body temperature increased—Docetaxel—prostate cancer	0.000182	0.000585	CcSEcCtD
Scopolamine—Arrhythmia—Doxorubicin—prostate cancer	0.00018	0.000581	CcSEcCtD
Scopolamine—Vision blurred—Epirubicin—prostate cancer	0.000179	0.000576	CcSEcCtD
Scopolamine—Mental disorder—Doxorubicin—prostate cancer	0.000177	0.000569	CcSEcCtD
Scopolamine—Abdominal pain—Capecitabine—prostate cancer	0.000176	0.000566	CcSEcCtD
Scopolamine—Body temperature increased—Capecitabine—prostate cancer	0.000176	0.000566	CcSEcCtD
Scopolamine—Vomiting—Etoposide—prostate cancer	0.000176	0.000566	CcSEcCtD
Scopolamine—Erythema—Doxorubicin—prostate cancer	0.000176	0.000566	CcSEcCtD
Scopolamine—Agitation—Epirubicin—prostate cancer	0.000174	0.000562	CcSEcCtD
Scopolamine—Rash—Etoposide—prostate cancer	0.000174	0.000561	CcSEcCtD
Scopolamine—Dermatitis—Etoposide—prostate cancer	0.000174	0.000561	CcSEcCtD
Scopolamine—Headache—Etoposide—prostate cancer	0.000173	0.000558	CcSEcCtD
Scopolamine—Fatigue—Prednisone—prostate cancer	0.000171	0.00055	CcSEcCtD
Scopolamine—Vertigo—Epirubicin—prostate cancer	0.000171	0.000549	CcSEcCtD
Scopolamine—Constipation—Prednisone—prostate cancer	0.000169	0.000546	CcSEcCtD
Scopolamine—Vision blurred—Doxorubicin—prostate cancer	0.000165	0.000533	CcSEcCtD
Scopolamine—Asthenia—Docetaxel—prostate cancer	0.000165	0.000531	CcSEcCtD
Scopolamine—Nausea—Etoposide—prostate cancer	0.000164	0.000529	CcSEcCtD
Scopolamine—Feeling abnormal—Prednisone—prostate cancer	0.000163	0.000526	CcSEcCtD
Scopolamine—Pruritus—Docetaxel—prostate cancer	0.000162	0.000524	CcSEcCtD
Scopolamine—Agitation—Doxorubicin—prostate cancer	0.000161	0.00052	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.00016	0.000517	CcSEcCtD
Scopolamine—Asthenia—Capecitabine—prostate cancer	0.00016	0.000514	CcSEcCtD
Scopolamine—Dry mouth—Epirubicin—prostate cancer	0.000158	0.000509	CcSEcCtD
Scopolamine—Vertigo—Doxorubicin—prostate cancer	0.000158	0.000508	CcSEcCtD
Scopolamine—Pruritus—Capecitabine—prostate cancer	0.000157	0.000507	CcSEcCtD
Scopolamine—Abdominal pain—Prednisone—prostate cancer	0.000157	0.000504	CcSEcCtD
Scopolamine—Body temperature increased—Prednisone—prostate cancer	0.000157	0.000504	CcSEcCtD
Scopolamine—Confusional state—Epirubicin—prostate cancer	0.000156	0.000503	CcSEcCtD
Scopolamine—Oedema—Epirubicin—prostate cancer	0.000155	0.000499	CcSEcCtD
Scopolamine—Nervous system disorder—Epirubicin—prostate cancer	0.000152	0.000489	CcSEcCtD
Scopolamine—Dizziness—Docetaxel—prostate cancer	0.000152	0.000489	CcSEcCtD
Scopolamine—Tachycardia—Epirubicin—prostate cancer	0.000151	0.000487	CcSEcCtD
Scopolamine—Skin disorder—Epirubicin—prostate cancer	0.00015	0.000485	CcSEcCtD
Scopolamine—Hyperhidrosis—Epirubicin—prostate cancer	0.00015	0.000482	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000148	0.000478	CcSEcCtD
Scopolamine—Dizziness—Capecitabine—prostate cancer	0.000147	0.000474	CcSEcCtD
Scopolamine—Dry mouth—Doxorubicin—prostate cancer	0.000146	0.000471	CcSEcCtD
Scopolamine—Vomiting—Docetaxel—prostate cancer	0.000146	0.00047	CcSEcCtD
Scopolamine—Rash—Docetaxel—prostate cancer	0.000145	0.000467	CcSEcCtD
Scopolamine—Hypotension—Epirubicin—prostate cancer	0.000145	0.000466	CcSEcCtD
Scopolamine—Dermatitis—Docetaxel—prostate cancer	0.000145	0.000466	CcSEcCtD
Scopolamine—Confusional state—Doxorubicin—prostate cancer	0.000145	0.000466	CcSEcCtD
Scopolamine—Headache—Docetaxel—prostate cancer	0.000144	0.000464	CcSEcCtD
Scopolamine—Oedema—Doxorubicin—prostate cancer	0.000143	0.000462	CcSEcCtD
Scopolamine—Asthenia—Prednisone—prostate cancer	0.000142	0.000458	CcSEcCtD
Scopolamine—Vomiting—Capecitabine—prostate cancer	0.000141	0.000456	CcSEcCtD
Scopolamine—Nervous system disorder—Doxorubicin—prostate cancer	0.000141	0.000453	CcSEcCtD
Scopolamine—Rash—Capecitabine—prostate cancer	0.00014	0.000452	CcSEcCtD
Scopolamine—Pruritus—Prednisone—prostate cancer	0.00014	0.000451	CcSEcCtD
Scopolamine—Dermatitis—Capecitabine—prostate cancer	0.00014	0.000451	CcSEcCtD
Scopolamine—Tachycardia—Doxorubicin—prostate cancer	0.00014	0.000451	CcSEcCtD
Scopolamine—Headache—Capecitabine—prostate cancer	0.000139	0.000449	CcSEcCtD
Scopolamine—Skin disorder—Doxorubicin—prostate cancer	0.000139	0.000449	CcSEcCtD
Scopolamine—Hyperhidrosis—Doxorubicin—prostate cancer	0.000139	0.000446	CcSEcCtD
Scopolamine—Somnolence—Epirubicin—prostate cancer	0.000138	0.000444	CcSEcCtD
Scopolamine—Nausea—Docetaxel—prostate cancer	0.000136	0.00044	CcSEcCtD
Scopolamine—Hypotension—Doxorubicin—prostate cancer	0.000134	0.000432	CcSEcCtD
Scopolamine—Fatigue—Epirubicin—prostate cancer	0.000134	0.00043	CcSEcCtD
Scopolamine—Constipation—Epirubicin—prostate cancer	0.000132	0.000427	CcSEcCtD
Scopolamine—Pain—Epirubicin—prostate cancer	0.000132	0.000427	CcSEcCtD
Scopolamine—Nausea—Capecitabine—prostate cancer	0.000132	0.000426	CcSEcCtD
Scopolamine—Dizziness—Prednisone—prostate cancer	0.000131	0.000422	CcSEcCtD
Scopolamine—Feeling abnormal—Epirubicin—prostate cancer	0.000128	0.000411	CcSEcCtD
Scopolamine—Somnolence—Doxorubicin—prostate cancer	0.000127	0.000411	CcSEcCtD
Scopolamine—Vomiting—Prednisone—prostate cancer	0.000126	0.000406	CcSEcCtD
Scopolamine—Rash—Prednisone—prostate cancer	0.000125	0.000402	CcSEcCtD
Scopolamine—Dermatitis—Prednisone—prostate cancer	0.000125	0.000402	CcSEcCtD
Scopolamine—Headache—Prednisone—prostate cancer	0.000124	0.0004	CcSEcCtD
Scopolamine—Fatigue—Doxorubicin—prostate cancer	0.000124	0.000398	CcSEcCtD
Scopolamine—Constipation—Doxorubicin—prostate cancer	0.000123	0.000395	CcSEcCtD
Scopolamine—Pain—Doxorubicin—prostate cancer	0.000123	0.000395	CcSEcCtD
Scopolamine—Body temperature increased—Epirubicin—prostate cancer	0.000122	0.000395	CcSEcCtD
Scopolamine—Abdominal pain—Epirubicin—prostate cancer	0.000122	0.000395	CcSEcCtD
Scopolamine—Feeling abnormal—Doxorubicin—prostate cancer	0.000118	0.000381	CcSEcCtD
Scopolamine—Nausea—Prednisone—prostate cancer	0.000118	0.000379	CcSEcCtD
Scopolamine—Abdominal pain—Doxorubicin—prostate cancer	0.000113	0.000365	CcSEcCtD
Scopolamine—Body temperature increased—Doxorubicin—prostate cancer	0.000113	0.000365	CcSEcCtD
Scopolamine—Asthenia—Epirubicin—prostate cancer	0.000111	0.000358	CcSEcCtD
Scopolamine—Pruritus—Epirubicin—prostate cancer	0.00011	0.000353	CcSEcCtD
Scopolamine—Asthenia—Doxorubicin—prostate cancer	0.000103	0.000331	CcSEcCtD
Scopolamine—Dizziness—Epirubicin—prostate cancer	0.000102	0.00033	CcSEcCtD
Scopolamine—Pruritus—Doxorubicin—prostate cancer	0.000101	0.000327	CcSEcCtD
Scopolamine—Vomiting—Epirubicin—prostate cancer	9.85e-05	0.000317	CcSEcCtD
Scopolamine—Rash—Epirubicin—prostate cancer	9.77e-05	0.000315	CcSEcCtD
Scopolamine—Dermatitis—Epirubicin—prostate cancer	9.76e-05	0.000314	CcSEcCtD
Scopolamine—Headache—Epirubicin—prostate cancer	9.7e-05	0.000313	CcSEcCtD
Scopolamine—Dizziness—Doxorubicin—prostate cancer	9.48e-05	0.000305	CcSEcCtD
Scopolamine—Nausea—Epirubicin—prostate cancer	9.2e-05	0.000296	CcSEcCtD
Scopolamine—Vomiting—Doxorubicin—prostate cancer	9.11e-05	0.000294	CcSEcCtD
Scopolamine—Rash—Doxorubicin—prostate cancer	9.04e-05	0.000291	CcSEcCtD
Scopolamine—Dermatitis—Doxorubicin—prostate cancer	9.03e-05	0.000291	CcSEcCtD
Scopolamine—Headache—Doxorubicin—prostate cancer	8.98e-05	0.000289	CcSEcCtD
Scopolamine—Nausea—Doxorubicin—prostate cancer	8.51e-05	0.000274	CcSEcCtD
Scopolamine—CHRM1—Signaling by GPCR—IL2—prostate cancer	1.13e-05	7.16e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL2—prostate cancer	1.12e-05	7.13e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TERT—prostate cancer	1.12e-05	7.13e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TERT—prostate cancer	1.12e-05	7.11e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—NOS3—prostate cancer	1.12e-05	7.08e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL2—prostate cancer	1.11e-05	7.06e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—PIK3CA—prostate cancer	1.11e-05	7.05e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TERT—prostate cancer	1.11e-05	7.04e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MDM2—prostate cancer	1.11e-05	7.02e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—RXRA—prostate cancer	1.09e-05	6.95e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—ERBB2—prostate cancer	1.09e-05	6.92e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—JAK2—prostate cancer	1.08e-05	6.88e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3CB—prostate cancer	1.08e-05	6.83e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HIF1A—prostate cancer	1.07e-05	6.82e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HIF1A—prostate cancer	1.07e-05	6.8e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—INS—prostate cancer	1.07e-05	6.78e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—PIK3CA—prostate cancer	1.06e-05	6.75e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HIF1A—prostate cancer	1.06e-05	6.73e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MDM2—prostate cancer	1.06e-05	6.72e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—COMT—prostate cancer	1.05e-05	6.69e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTP1—prostate cancer	1.05e-05	6.66e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—LEP—prostate cancer	1.05e-05	6.66e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—CREBBP—prostate cancer	1.05e-05	6.64e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—LEP—prostate cancer	1.05e-05	6.64e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—ERBB2—prostate cancer	1.04e-05	6.63e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CAV1—prostate cancer	1.04e-05	6.6e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CAV1—prostate cancer	1.04e-05	6.57e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—LEP—prostate cancer	1.04e-05	6.57e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CXCL8—prostate cancer	1.03e-05	6.56e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ITPR1—prostate cancer	1.03e-05	6.55e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3CB—prostate cancer	1.03e-05	6.54e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KDR—prostate cancer	1.03e-05	6.52e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CAV1—prostate cancer	1.03e-05	6.51e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KDR—prostate cancer	1.02e-05	6.5e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KDR—prostate cancer	1.01e-05	6.44e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CDKN1B—prostate cancer	1.01e-05	6.41e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ESR1—prostate cancer	1e-05	6.36e-05	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—AKT1—prostate cancer	9.99e-06	6.34e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ESR1—prostate cancer	9.98e-06	6.34e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CD—prostate cancer	9.92e-06	6.3e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CXCL8—prostate cancer	9.9e-06	6.28e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CASP3—prostate cancer	9.9e-06	6.28e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ESR1—prostate cancer	9.89e-06	6.27e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL2—prostate cancer	9.88e-06	6.27e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL6—prostate cancer	9.83e-06	6.24e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—BAD—prostate cancer	9.78e-06	6.2e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—TYMS—prostate cancer	9.76e-06	6.19e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—BAD—prostate cancer	9.74e-06	6.18e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CDKN1B—prostate cancer	9.67e-06	6.14e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—BAD—prostate cancer	9.65e-06	6.12e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTM1—prostate cancer	9.64e-06	6.12e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCND1—prostate cancer	9.63e-06	6.11e-05	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—AKT1—prostate cancer	9.56e-06	6.07e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CTNNB1—prostate cancer	9.54e-06	6.05e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CASP3—prostate cancer	9.48e-06	6.01e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—APC—prostate cancer	9.47e-06	6.01e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	9.47e-06	6.01e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—LPL—prostate cancer	9.47e-06	6.01e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL2—prostate cancer	9.46e-06	6e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—APC—prostate cancer	9.44e-06	5.99e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	9.44e-06	5.99e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL6—prostate cancer	9.41e-06	5.97e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—NOS3—prostate cancer	9.37e-06	5.95e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EGF—prostate cancer	9.36e-06	5.94e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IRS1—prostate cancer	9.36e-06	5.94e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MMP9—prostate cancer	9.35e-06	5.93e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	9.35e-06	5.93e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—APC—prostate cancer	9.35e-06	5.93e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EGF—prostate cancer	9.33e-06	5.92e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IRS1—prostate cancer	9.33e-06	5.92e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CDKN1A—prostate cancer	9.32e-06	5.91e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PTEN—prostate cancer	9.3e-06	5.9e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IRS1—prostate cancer	9.24e-06	5.86e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EGF—prostate cancer	9.24e-06	5.86e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCND1—prostate cancer	9.22e-06	5.85e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CYP1A1—prostate cancer	9.14e-06	5.8e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CTNNB1—prostate cancer	9.13e-06	5.8e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—GSK3B—prostate cancer	9.08e-06	5.77e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—AKT1—prostate cancer	9.07e-06	5.76e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ERCC2—prostate cancer	9.07e-06	5.75e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—GSK3B—prostate cancer	9.06e-06	5.75e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—GSK3B—prostate cancer	8.97e-06	5.69e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—INS—prostate cancer	8.96e-06	5.69e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MMP9—prostate cancer	8.96e-06	5.68e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—INS—prostate cancer	8.93e-06	5.67e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CDKN1A—prostate cancer	8.92e-06	5.66e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PTEN—prostate cancer	8.9e-06	5.65e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—EP300—prostate cancer	8.87e-06	5.63e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—INS—prostate cancer	8.85e-06	5.61e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CREBBP—prostate cancer	8.78e-06	5.57e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CREBBP—prostate cancer	8.75e-06	5.55e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—AKT1—prostate cancer	8.69e-06	5.51e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IGF1—prostate cancer	8.67e-06	5.5e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CREBBP—prostate cancer	8.66e-06	5.5e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CB—prostate cancer	8.65e-06	5.49e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IGF1—prostate cancer	8.64e-06	5.48e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—EGFR—prostate cancer	8.63e-06	5.47e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—SRC—prostate cancer	8.62e-06	5.47e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—EGFR—prostate cancer	8.6e-06	5.46e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTGS2—prostate cancer	8.57e-06	5.44e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IGF1—prostate cancer	8.56e-06	5.43e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—MTHFR—prostate cancer	8.52e-06	5.41e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—EGFR—prostate cancer	8.51e-06	5.4e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—EP300—prostate cancer	8.49e-06	5.39e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—VEGFA—prostate cancer	8.4e-06	5.33e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	8.38e-06	5.32e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PPARA—prostate cancer	8.36e-06	5.31e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	8.35e-06	5.3e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	8.32e-06	5.28e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—STAT3—prostate cancer	8.31e-06	5.28e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	8.3e-06	5.26e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	8.27e-06	5.25e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—SRC—prostate cancer	8.26e-06	5.24e-05	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	8.24e-06	5.23e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	8.23e-06	5.22e-05	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	8.22e-06	5.21e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	8.22e-06	5.21e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	8.21e-06	5.21e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—KRAS—prostate cancer	8.15e-06	5.17e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	8.14e-06	5.16e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	8.13e-06	5.16e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—KRAS—prostate cancer	8.12e-06	5.15e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—KRAS—prostate cancer	8.04e-06	5.1e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—VEGFA—prostate cancer	8.04e-06	5.1e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—FGF2—prostate cancer	7.97e-06	5.06e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—STAT3—prostate cancer	7.96e-06	5.05e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—FGF2—prostate cancer	7.94e-06	5.04e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—FGF2—prostate cancer	7.87e-06	4.99e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CAV1—prostate cancer	7.86e-06	4.99e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—NOS3—prostate cancer	7.86e-06	4.99e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—NOS3—prostate cancer	7.83e-06	4.97e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—NOS3—prostate cancer	7.76e-06	4.92e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MYC—prostate cancer	7.73e-06	4.9e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TGFB1—prostate cancer	7.71e-06	4.89e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—JAK2—prostate cancer	7.64e-06	4.85e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—JAK2—prostate cancer	7.61e-06	4.83e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—EGFR—prostate cancer	7.56e-06	4.8e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—JAK2—prostate cancer	7.54e-06	4.78e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	7.49e-06	4.75e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTEN—prostate cancer	7.47e-06	4.74e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	7.46e-06	4.74e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MDM2—prostate cancer	7.46e-06	4.73e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MDM2—prostate cancer	7.43e-06	4.72e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MYC—prostate cancer	7.4e-06	4.69e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	7.39e-06	4.69e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TGFB1—prostate cancer	7.38e-06	4.68e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MDM2—prostate cancer	7.36e-06	4.67e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ERBB2—prostate cancer	7.35e-06	4.66e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ERBB2—prostate cancer	7.33e-06	4.65e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ERBB2—prostate cancer	7.26e-06	4.6e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	7.25e-06	4.6e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—EGFR—prostate cancer	7.24e-06	4.59e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	7.23e-06	4.59e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CG—prostate cancer	7.16e-06	4.54e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	7.16e-06	4.54e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—KRAS—prostate cancer	7.14e-06	4.53e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—EP300—prostate cancer	7.13e-06	4.52e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CXCL8—prostate cancer	6.97e-06	4.42e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CXCL8—prostate cancer	6.95e-06	4.41e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CXCL8—prostate cancer	6.88e-06	4.37e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—KRAS—prostate cancer	6.84e-06	4.34e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	6.81e-06	4.32e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	6.79e-06	4.31e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—INS—prostate cancer	6.78e-06	4.3e-05	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	6.73e-06	4.27e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	6.72e-06	4.26e-05	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	6.71e-06	4.26e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CASP3—prostate cancer	6.67e-06	4.23e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL2—prostate cancer	6.66e-06	4.23e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CASP3—prostate cancer	6.65e-06	4.22e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	6.65e-06	4.22e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL2—prostate cancer	6.64e-06	4.21e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CREBBP—prostate cancer	6.64e-06	4.21e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL6—prostate cancer	6.63e-06	4.21e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL6—prostate cancer	6.61e-06	4.19e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CASP3—prostate cancer	6.59e-06	4.18e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL2—prostate cancer	6.58e-06	4.17e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	6.56e-06	4.16e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL6—prostate cancer	6.54e-06	4.15e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCND1—prostate cancer	6.49e-06	4.12e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCND1—prostate cancer	6.47e-06	4.11e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	6.43e-06	4.08e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCND1—prostate cancer	6.41e-06	4.07e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	6.41e-06	4.07e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	6.35e-06	4.03e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TP53—prostate cancer	6.34e-06	4.03e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MMP9—prostate cancer	6.31e-06	4e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CD—prostate cancer	6.3e-06	3.99e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MMP9—prostate cancer	6.29e-06	3.99e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	6.28e-06	3.99e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	6.28e-06	3.99e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PTEN—prostate cancer	6.27e-06	3.98e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	6.26e-06	3.97e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PTEN—prostate cancer	6.25e-06	3.97e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MMP9—prostate cancer	6.22e-06	3.95e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	6.2e-06	3.94e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PTEN—prostate cancer	6.19e-06	3.93e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	6.12e-06	3.88e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—AKT1—prostate cancer	6.1e-06	3.87e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TP53—prostate cancer	6.08e-06	3.86e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	6.04e-06	3.83e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EP300—prostate cancer	5.98e-06	3.79e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EP300—prostate cancer	5.96e-06	3.78e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—NOS3—prostate cancer	5.94e-06	3.77e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EP300—prostate cancer	5.9e-06	3.74e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—SRC—prostate cancer	5.81e-06	3.69e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL6—prostate cancer	5.81e-06	3.69e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—SRC—prostate cancer	5.79e-06	3.68e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—SRC—prostate cancer	5.74e-06	3.64e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	5.66e-06	3.59e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—VEGFA—prostate cancer	5.64e-06	3.58e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—STAT3—prostate cancer	5.61e-06	3.56e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	5.59e-06	3.55e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—STAT3—prostate cancer	5.59e-06	3.55e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL6—prostate cancer	5.56e-06	3.53e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—STAT3—prostate cancer	5.53e-06	3.51e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CB—prostate cancer	5.49e-06	3.48e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTGS2—prostate cancer	5.44e-06	3.45e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—AKT1—prostate cancer	5.36e-06	3.4e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CA—prostate cancer	5.27e-06	3.35e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MYC—prostate cancer	5.21e-06	3.31e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	5.2e-06	3.3e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MYC—prostate cancer	5.19e-06	3.3e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TGFB1—prostate cancer	5.18e-06	3.29e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MYC—prostate cancer	5.14e-06	3.26e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—AKT1—prostate cancer	5.13e-06	3.26e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	5.13e-06	3.26e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EGFR—prostate cancer	5.1e-06	3.23e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EGFR—prostate cancer	5.08e-06	3.22e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EGFR—prostate cancer	5.03e-06	3.19e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KRAS—prostate cancer	4.81e-06	3.05e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KRAS—prostate cancer	4.8e-06	3.04e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KRAS—prostate cancer	4.75e-06	3.02e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTEN—prostate cancer	4.74e-06	3.01e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—EP300—prostate cancer	4.52e-06	2.87e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	4.42e-06	2.81e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	4.41e-06	2.8e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	4.37e-06	2.77e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—AKT1—prostate cancer	4.31e-06	2.73e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TP53—prostate cancer	4.28e-06	2.71e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TP53—prostate cancer	4.26e-06	2.71e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TP53—prostate cancer	4.22e-06	2.68e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL6—prostate cancer	3.92e-06	2.48e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL6—prostate cancer	3.9e-06	2.48e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL6—prostate cancer	3.87e-06	2.45e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—AKT1—prostate cancer	3.61e-06	2.29e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—AKT1—prostate cancer	3.6e-06	2.29e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—AKT1—prostate cancer	3.57e-06	2.26e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CA—prostate cancer	3.35e-06	2.12e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—AKT1—prostate cancer	2.73e-06	1.73e-05	CbGpPWpGaD
